The clinical response to immune checkpoint blockade (ICB) correlates with tumor-infiltrating cytolytic T lymphocytes (CTLs) prior to treatment. However, many of these inflamed tumors resist ICB through unknown mechanisms. We show that tumors with transcription elongation deficiencies (TEdef+), which we previously reported as being resistant to ICB in mouse models and the clinic, have high baseline CTLs. We show that high baseline CTLs in TEdef+ tumors result from aberrant activation of the nucleic acid sensing-TBK1-CCL5/CXCL9 signaling cascade, which results in an immunosuppressive microenvironment with elevated regulatory T cells and exhausted CTLs. ICB therapy of TEdef+ tumors fail to increase CTL infiltration and suppress tumor growth in both experimental and clinical settings, suggesting that TEdef+, along with surrogate markers of tumor immunogenicity such as tumor mutational burden and CTLs, should be considered in the decision process for patient immunotherapy indication.
Pubmed ID: 37043352 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets CD4
View all literature mentionsThis monoclonal targets FOXP3
View all literature mentionsThis monoclonal targets HLA-A
View all literature mentionsThis monoclonal targets ACTB
View all literature mentionsThis polyclonal targets H3K36me3
View all literature mentionsThis monoclonal targets RNA pol II
View all literature mentionsThis monoclonal targets RNA pol II CTD phospho Ser5
View all literature mentionsThis monoclonal targets RNA pol II CTD
View all literature mentionsThis monoclonal targets CTLA-4 (CD152)
View all literature mentionsThis monoclonal targets PD-1 (CD279)
View all literature mentionsThis monoclonal targets Mouse CCL5/RANTES Affinity Purified Ab
View all literature mentionsThis monoclonal targets CXCL10
View all literature mentionsThis monoclonal targets CXCL9
View all literature mentionsThis monoclonal targets FOXP3
View all literature mentionsThis monoclonal targets CD366
View all literature mentionsThis monoclonal targets CD195
View all literature mentionsThis monoclonal targets CD4
View all literature mentions